Cell-Based Gene Therapy for b-Thalassemia
Related Experiment Video
Updated: Aug 4, 2025

Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
Published on: November 4, 2018
Yajika Arya1, Puneet Kaur Sahi2
1Department of Pediatrics, Maulana Azad Medical College (University of Delhi) and associated Lok Nayak Hospital, New Delhi. Correspondence to: Dr Yajika Arya, Senior Resident, Department of Pediatrics, Lok Nayak Hospital, New Delhi 110 002. yajikachutani95@gmail.com.
Abstract:
The United States Food and Drug Administration (FDA) approved betibeglogene autotemcel (beti-cel), the first cell-based gene therapy for adult and pediatric patients with b-thalassemia in August, 2022. This update details this and other novel therapies that have emerged in the treatment of b-thalassemia, apart from transfusion and iron chelation, with particular focus on newly approved gene therapy.
More Related Videos
08:32CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
Published on: August 9, 2022
11:59Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies
Published on: September 6, 2017
Related Concept Videos
Gene Therapy
iPS Cell Differentiation
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...